DFTX

Definium Therapeutics, Inc.

NasdaqAdd to watchlist

$37.99

−$0.24−0.63%

Delayed · 2026-09-09T20:00:00.000Z · marketstack

2 of 47tracked managers hold this· Q2 2026

Aug 10, 2026$37.99

−$7.16−15.86%over 1M

Day range25% of range

$37.68$38.93

Session

Previous close: $38.23
Open: $37.82
Volume: 1.29M
Avg volume: -
Day high: $38.93
Day low: $37.68

Fundamentals

Visualize fundamentals and more

Market cap: 4.2B
P/E ratio: -
EPS (TTM): -$3.20
Dividend yield: -
Beta: -
Shares outstanding: 110.68M

Source SEC EDGAR · 9/10/2026

Tracked investors

As of Q2 2026 · 72 days ago · next update ~14 Nov 2026· what moved this quarter, onMeasure

2 fund managers this platform follows disclosed a position here, from quarterly SEC filings up to 45 days old; a manager may have sold since without yet having to say so.

Stanley Druckenmiller
Duquesne Family Office
$16.77M
0.39%of book
Joel Greenblatt
Gotham Asset Management
$207.54K
<0.01%of book

Manager	Position	Share of their book	Last change
Stanley Druckenmiller Duquesne Family Office	$16.77M	0.39%
Joel Greenblatt Gotham Asset Management	$207.54K	<0.01%

Share price, with each quarter a tracked manager’s position changed shaded across the range it traded in.

20304050

now

Q2 '26

Hover a shaded quarter to see it moved. Who, and the range they traded in, is onBespoke

13F filings cover US-listed shares only (not cash, bonds, shorts, or private holdings) and are never a recommendation to do the same.

Risk factors, year on year

Item 1AFebruary 2026 10-KMarch 2025as filed.

added: 35
dropped: 28
re-drafted: 81

Out of 313 passages in this year’s Item 1A.

New this year

will continue to have an adverse effect on our working capital, our ability to fund the development of our product candidates and our ability to achieve and maintain profitability and the performance of our common shares.

62 more passages, included withBespoke

Recent activity

Sep 8Other eventCompany filing8-K

Sep 3Barrow Robert sold 19,023 sharesInsider tradingForm 4Chief Executive Officer, about $722k, pre-planned (10b5-1)
Aug 12Regulation FD disclosureCompany filing8-K
Aug 6Results announcementCompany filing8-K

9 more events, included withMeasure

Discussion

No comments yet

Set a username to join the discussion. It’s the only thing shown next to what you post, never your email address.

Comments are written by other users. Nothing here is investment advice and nothing is checked for accuracy.

Ask about Definium Therapeutics, Inc.

The assistant answers from what DFTX has actually filed: 6 annual reports filed with the SEC, 37 Form 4 filings from the last year, 13F positions from the 2 tracked investors who hold it and 2 funds that hold it. Every figure in a reply links to the filing it came from, so an answer can be checked rather than believed.

Pressing one answers it here, from DFTX's filings and figures. One a day without an account; a free account has its own, and no card.

See every investor holding Definium Therapeutics, Inc., and every quarter they moved.

Ten seconds, no card, and nothing to cancel.

No card, no broker connection.

Continue with Google

Separate the decisions from the paperwork
Every Form 4 DFTX insiders have filed, with vesting and automatic tax sales struck out: what's left is the buys and sells somebody actually chose to make.
Every filingMeasure
Watch the same stakes the professionals are watching
Every tracked position priced at the quarter it was filed and diffed against the one before it: who added, who trimmed, who walked away.
Every position they holdMeasure
Interrogate the filing, not the internet
Ask anything about Definium Therapeutics, Inc.'s fundamentals. The assistant answers from its own filings and cites the figure, never a guess from the open web.

Session

Fundamentals

Risk factors, year on year

Recent activity

Discussion

Ask about Definium Therapeutics, Inc.

What an account lets you do with Definium Therapeutics, Inc.

Recent activity

Risk factors, year on year